While America undertakes sweeping revisions to its vaccine schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations in the global health crisis and has concentrated on possible deaths following COVID-19 immunization in her short position at the FDA.
Scheduled Overhauls to Childhood Vaccine Program
Agency leaders planned to unveil radical revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would place the US out of alignment with a large portion of the global community with no evidence for public health gain. The announcement has been postponed until the new year.
Instead of the top vaccines chief, Tracy Beth Høeg is set to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.
A Shift at the Agency
Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling previously authorized vaccines at the FDA.
Dr. Høeg has repeatedly called for discontinuing specific childhood immunization guidelines in the US in order to be more like Denmark, a society with universal health coverage and a population approximately the size of the state of Wisconsin.
In her initial statements, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.
Doubts Over Background
Høeg has no obvious experience in medication creation, regulation or administrative roles, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and CBER since March.
“She doesn’t seem to have any of the qualifications” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in managing a large organization. She is not an expert in pharmaceutical oversight.”
Past commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the type of experience that former directors who ran the center have had.”
The drug center has an immense portfolio at the FDA, Woodcock emphasized.
“Everybody just zeroes in on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and each of these must be looked after,” Dr. Woodcock noted. “The thing you neglect, that is the part that I always told people is going to bite you.”
There is also, a significant management component to the role, which oversees over 5,000 staff members. “It is a enormous management job, if you do it right,” she added.
Agency Reaction and Contentious Initiatives
In response to concerns about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a representative stated that the “inquiries stem from flawed presumptions”.
“Her experience matches the responsibilities of her position,” the spokesperson said, noting the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.
As the temporary head, Høeg inherits the commissioner’s new fast-track approval initiative, a contentious one-day therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being picked for this voucher program? Who is making the choices?” Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”
Overall, he stated, “the FDA looks to be trending towards laxer oversight of pharmaceuticals, except for immunizations.”
Documented Track Record on Vaccines
Regarding vaccines, Høeg has a clearer, if troubling, track record, critics have noted. She published a study using non-validated volunteer-provided data to determine the rate of myocarditis following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.
Part of her “policy goals” for the incoming government encompassed changing guidelines for recently developed shots and ending “optional” immunizations, she remarked following the vote on a online show. At the agency, Høeg has allegedly suggested barring young men from obtaining Covid vaccines.
“She is an thorough dogmatist who begins with her conclusions and reverse-engineers to fit the evidence in a extremely misleading, dishonest way,” Howard argued.
Gaining Influence and a “Campaign of Retribution”
Dr. Høeg aligned with fellow dissenters, {like|